USFDA concludes GMP inspection at Gland Pharma’s Dundigal facility

14 Jul 2023 Evaluate

United States Food and Drug Administration (USFDA) has concluded Good Manufacturing Practice (GMP) Inspection at the Gland Pharma’s Dundigal Facility at Hyderabad between July 03, 2023 and July 14, 2023. The inspection was concluded with (1) 483 Observation. 

The corrective and preventive actions for this observation will be submitted to the US FDA within the stipulated period. The observation issued is neither a repeated observation nor related to data integrity.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1821.00 -15.25 (-0.83%)
20-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.45
Dr. Reddys Lab 1280.30
Cipla 1341.45
Zydus Lifesciences 901.00
Lupin 2219.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×